Skip to content
    MED
    Earnings call· Jun 2026(Q2 FY26)

    MEDIFAST Q2 FY26 earnings call MED

    Aug 3, 2026 Source

    Executive summary

    Medifast Q2 FY26 — Strategic Shift to Metabolic Health with Trilivi Launch

    Medifast is undergoing a significant strategic transition, launching its new Trilivi brand and 3.0 strategy focused on comprehensive metabolic health. Despite a decline in active coaches and revenue, the company reported strong coach productivity and met its Q2 revenue and earnings expectations. Management is focused on returning to profitability by Q4 2026 through cost-saving initiatives and the new product line, leveraging its strong balance sheet and scientific heritage.

    Highlights

    4

    • Active earning coach productivity up 41% YoY and 20% sequentially, reaching highest level since Q2 2022.

    • Ended the quarter with $169.8 million in cash and investments and no debt, maintaining a strong balance sheet.

    • Q2 revenue of $76 million met guidance, reflecting positive operating indicators and improved client retention.

    • Enhanced compensation plan launched August 1st to accelerate growth by focusing on Executive Directors, who remain over the 10% benchmark.

    Concerns

    4

    • Revenue decreased 27.6% YoY to $76.4 million, primarily due to a decline in active earning coaches.

    • Active earning coach count decreased 48.7% YoY to approximately 11,700.

    • Gross profit decreased 30.3% YoY to $53.4 million, with gross profit margin declining to 69.9% from 72.6% due to loss of leverage on fixed costs.

    • Net loss of $3.1 million, or $0.28 per diluted share, compared to net income of $2.5 million, or $0.22 per share, in the prior year.

    Guidance & targets

    8
    CategoryTargetConfidence
    Q3 FY26 Revenue
    $60 million to $80 million
    high materiality
    High
    Q3 FY26 Loss Per Share
    $0.15 to $0.65
    high materiality
    High
    Full-Year FY26 Revenue
    $270 million to $300 million
    high materiality
    High
    Full-Year FY26 Loss Per Share
    $0.25 to $1.75
    high materiality
    High
    Return to Profitability
    Q4 2026
    high materiality
    High
    Working Capital
    >$145 million
    medium materiality
    High
    Coach Productivity Growth
    continued growth
    medium materiality
    High
    Earnings Improvement
    continue into 2027 and beyond
    medium materiality
    Medium

    Operational metrics

    25
    Revenue
    $76.4 milliondown 27.6% YoY
    Q2 FY26

    Primarily due to a decrease in the number of active earning coaches.

    Active Earning Coaches
    11,700down 48.7% from Q2 FY25
    Q2 FY26

    The company continues to see an impact from rapid growth.

    Revenue per Active Earning Coach
    $6,529up 41.0% YoY
    Q2 FY26

    Highest since Q2 2022, showing a clear trend of increasing productivity.

    Gross Profit
    $53.4 milliondown 30.3% YoY
    Q2 FY26

    Driven by lower sales volumes.

    Gross Profit Margin
    69.9%vs 72.6% in Q2 FY25
    Q2 FY26

    Primarily driven by the loss of leverage on fixed costs.

    SG&A Expense
    $57.7 milliondown 25.7% YoY
    Q2 FY26

    Primarily due to decreases in coach compensation, employment, employee salary and benefit expenses, and company-led marketing costs.

    SG&A as Percentage of Revenue
    increased 200 bps
    Q2 FY26

    Primarily due to loss of leverage on fixed costs and the Trilogy Reset product line launch, partially offset by reduced company-led marketing costs.

    Loss from Operations
    $4.3 millionincrease of $3.3 million YoY
    Q2 FY26

    Decline in gross profit was largely offset by lower SG&A.

    Loss from Operations as Percentage of Revenue
    5.7%470 bps change from 1.0% in Q2 FY25
    Q2 FY26

    Reflects the increased loss from operations.

    Other Income
    $1.3 milliondecreased $2.6 million YoY
    Q2 FY26

    Primarily due to gains on LifeMD common stock investment in the year-earlier period, which was sold in Q2 2025.

    Income Tax Expense
    $0.1 millionvs $0.4 million in Q2 FY25
    Q2 FY26

    Calculated based on actual results due to a full valuation allowance against deferred tax assets.

    Effective Tax Rate
    negative 3.6%vs 13.7% in Q2 FY25
    Q2 FY26

    Primarily driven by the increased loss incurred and the valuation allowance on net deferred tax assets.

    Net Loss
    $3.1 millionvs net income of $2.5 million in Q2 FY25
    Q2 FY26

    Reflects the overall financial performance for the quarter.

    Diluted EPS
    $0.28vs $0.22 per share in Q2 FY25
    Q2 FY26

    Reflects the overall financial performance for the quarter.

    Cash, Cash Equivalents, and Investments
    $169.8 million
    Q2 FY26

    Company holds no debt as of June 30, 2026.

    Working Capital
    $160.5 million
    FY25

    Defined as current assets less current liabilities, as of December 31, 2025.

    Metabolically Unhealthy Adults Worldwide
    1.5 billion
    current

    More than 90% of US adults are also metabolically unhealthy.

    Adults Concerned About Metabolic Health
    94%
    current

    Concerned about at least one aspect of their metabolic health.

    Adults Believing Metabolic Dysfunction Can Be Reversed
    85%
    current

    Belief that metabolic dysfunction can be reversed.

    Adults Seeing Metabolic Health as Central to Well-being
    84%
    current

    See metabolic health as central to overall well-being, despite 80% not understanding what it means.

    Visceral Fat Reduction
    14%
    16 weeks

    Achieved while retaining 98% of lean mass.

    Lean Mass Retention
    98%
    16 weeks

    Achieved while reducing visceral fat by 14%.

    Weight Loss with Coach
    up to 10 times morevs trying on their own
    clinical study

    Clients working with a coach lost up to 10 times more weight and 17 times more fat.

    Fat Loss with Coach
    17 times morevs trying on their own
    clinical study

    Clients working with a coach lost up to 10 times more weight and 17 times more fat.

    Executive Director Rank or Above Coaches
    over 10%
    Q2 FY26

    Percentage of active earning coaches at Executive Director rank or above continues to climb, remaining over the benchmark for a healthy, scalable field organization.

    Industry KPIs

    3
    MetricValueDetails
    Brand marketing investmentdecreased $2 millionUSD
    Productivity cost savings programmillions of savingsUSD
    Underlying operating margin bridge5.7%%

    Product announcements

    3
    ProductTypeDetails
    Trilivilaunch
    Medifast Metabolic Health Institutelaunch
    Reset Fuelings (Medivantage Technology)launch

    Risks & headwinds

    4
    Decline in Active Earning CoachesQ2 FY26

    down 48.7% YoY to 11,700

    Mitigation: Enhanced compensation plan, focus on Executive Directors, new brand launch (Trilivi) and product offerings to drive coach engagement and growth.

    Loss of Leverage on Fixed CostsQ2 FY26

    Gross profit margin decreased from 72.6% to 69.9% (270 bps impact on SG&A as % of revenue)

    Mitigation: Catalyst program for cost savings and efficiency, expected stabilization and growth of the business into 2027 to improve leverage.

    Initial Costs of Catalyst ProgramQ3 FY26

    One-time costs (not yet quantified)

    Mitigation: These costs are excluded from Q3 EPS guidance and will be called out in Q3 earnings. Expected to lead to 'millions of savings' in the long term.

    Market Understanding of Metabolic Healthcurrent

    80% of adults do not understand what metabolic health means

    Mitigation: Medifast Metabolic Health Institute to provide evidence-based education and establish the company as a trusted authority; coach-guided system to close the understanding gap.

    What to watch in Q3 FY26

    5

    Catalyst Program Savings Quantification

    Q3 FY26 earnings call
    Currentmillions of savings (unquantified)
    Targetquantified savings details

    Why it matters

    Quantification of Catalyst program savings is crucial for assessing the company's path to profitability and the effectiveness of its cost-reduction efforts.

    What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce. [...] We are going to be doing that in our Q3 earnings call.

    Q&A highlights

    2

    Analyst inquired about the initial implementation costs, expected savings, and cadence of the Catalyst Program, and whether it's the sole driver for Q4 2026 profitability or if other factors like top-line recovery and new product launches contribute.

    Management stated that specific quantification of Catalyst program savings would be provided in the Q3 earnings call, but confirmed it involves 'millions of savings' focused on simplifying the business without impacting top-line revenue. They clarified that Q4 profitability is also supported by the new product line launch and stabilization of the top line, noting that the full-year EPS range has improved.

    “What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce.”

    asked by James Salera · answered by Unknown Speaker

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Shift to Metabolic Health with Trilivi

    Medifast is executing its 3.0 strategy, marking the biggest shift since Optivia's 2017 launch. This 10-year roadmap aims to expand offerings to coaches and clients within a comprehensive metabolic health system, broadening geographic and demographic footprints. The new consumer brand, Trilivi, replaces Optivia, reflecting a holistic health approach beyond just weight loss, focusing on metabolic reset through three phases: reset, refine, and renew. This strategy is underpinned by speed, simplicity, scale, and stewardship.

    02

    Metabolic Health Institute and Science-Backed Products

    The company launched the Medifast Metabolic Health Institute in July, dedicated to advancing metabolic health through research and evidence-based education. This institute, led by experts with over 390 years of collective experience, aims to strengthen the evidence base for programs and establish Medifast as a trusted authority. Concurrently, new Reset Fuelings, utilizing proprietary Medivantage Technology, are launching later this month. These fuelings are designed to support normal fat metabolism, healthy insulin function, and reduced waist circumference, anchoring the clinically proven Reset 5-in-1 Plan.

    03

    Coach Engagement and Compensation Enhancements

    Despite a decline in the overall number of coaches, active earning coach productivity has shown positive trends for the third consecutive quarter, up 41% YoY and 20% sequentially. Revenue per active earning coach is at its highest since Q2 2022. An enhanced compensation plan launched on August 1st aims to further accelerate growth by focusing on developing Executive Directors, who are key drivers of sustainable growth and remain above the 10% benchmark for a healthy field organization. The client referral program also continues to exceed expectations.

    04

    Catalyst Program for Cost Savings and Profitability

    Medifast initiated its Catalyst program in Q2, with the majority of execution expected in Q3. This program targets additional cost savings through facility rationalization, AI-related efficiencies, and other means, without impacting growth capabilities. The Catalyst program is a key component in the company's objective to return to profitability by Q4 2026, with further earnings improvements targeted for 2027 and beyond. Management expects to share more quantified details on savings in the Q3 earnings call.

    05

    Market Opportunity and GLP-1 Engagement

    The company highlights a significant market opportunity, noting that over 90% of US adults and 1.5 billion worldwide are metabolically unhealthy, yet 80% lack understanding of metabolic health. Medifast's coach-guided system aims to bridge this gap. The company continues to engage with the GLP-1 market, supporting individuals whether they are using medication, coming off it, or pursuing non-medication pathways, emphasizing holistic lifestyle change and behavioral modification.

    AI-generated summary of the company’s earnings call. Not investment advice.